Affiner les résultats

Patient-doctor agreement on recall of clinical trial discussion across cultures

Bernhard, J. ; Aldridge, J. ; Butow, P. N. ; Zoller, P. ; Brown, R. ; Smith, A. ; Juraskova, I.

In: Annals of Oncology, 2013, vol. 24, no. 2, p. 391-397

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report

Karlsson, P. ; Cole, B. F. ; Chua, B. H. ; Price, K. N. ; Lindtner, J. ; Collins, J. P. ; Kovács, A. ; Thürlimann, B. ; Crivellari, D. ; Castiglione-Gertsch, M. ; Forbes, J. F. ; Gelber, R. D. ; Goldhirsch, A. ; Gruber, G.

In: Annals of Oncology, 2012, vol. 23, no. 11, p. 2852-2858

Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study

Belkacémi, Y. ; Gligorov, J. ; Ozsahin, M. ; Marsiglia, H. ; De Lafontan, B. ; Laharie-Mineur, H. ; Aimard, L. ; Antoine, E.-C ; Cutuli, B. ; Namer, M. ; Azria, D.

In: Annals of Oncology, 2008, vol. 19, no. 6, p. 1110-1116

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer : Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

Thürlimann, B. ; Beretta, K. ; Bacchi, M. ; Castiglione-Gertsch, M. ; Goldhirsch, A. ; Jungi, W. F. ; Cavalli, F. ; Senn, H.-J ; Fey, M. ; Löhnert, T.

In: Annals of Oncology, 1996, vol. 7, no. 5, p. 471-479

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial

Dedes, K J.

In: Annals of Oncology, 2007, vol. 18, no. 9, p. 1493-1499

New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction?

Goldhirsch, A. ; Coates, A. S. ; Castiglione-Gertsch, M. ; Gelber, R. D.

In: Annals of Oncology, 1998, vol. 9, no. 9, p. 973-976

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer

Gruber, G. ; Cole, B. F. ; Castiglione-Gertsch, M. ; Holmberg, S. B. ; Lindtner, J. ; Golouh, R. ; Collins, J. ; Crivellari, D. ; Thürlimann, B. ; Simoncini, E. ; Fey, M. F. ; Gelber, R. D. ; Coates, A. S. ; Price, K. N. ; Goldhirsch, A. ; Viale, G. ; Gusterson, B. A.

In: Annals of Oncology, 2008, vol. 19, no. 8, p. 1393-1401

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

Mauriac, L. ; Keshaviah, A. ; Debled, M. ; Mouridsen, H. ; Forbes, JF ; Thürlimann, B. ; Paridaens, R. ; Monnier, A. ; Láng, I. ; Wardley, A. ; Nogaret, J-M ; Gelber, RD ; Castiglione-Gertsch, M. ; Price, KN ; Coates, AS ; Smith, I. ; Viale, G. ; Rabaglio, M. ; Zabaznyi, N. ; Goldhirsch, A.

In: Annals of Oncology, 2007, vol. 18, no. 5, p. 859-867

Pflegerische Interventioen zur Prävention und Behandlung strahleninduzierter Dermatitis bei Mammakarzinom-Patientinnen : systematische Literaturübersicht

Zehnder, Sarah ; Eicher, Manuela (Dir.)

Mémoire de bachelor : Haute Ecole de Santé de Fribourg, 2011.

Die vorliegende Bachelorthesis hat den Charakter einer systematischen Literaturübersicht. Das Ziel dieser Bachelorthesis besteht im Analysieren und Ermitteln von evidenzbasierten Pflegeinterventionen zur Prävention und Behandlung von strahleninduzierter Dermatitis bei Mammakarzinom-Patientinnen. Für die Literaturanalyse wurden fünf Datenbanken auf Studien mit experimentellem oder quasi-...

In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FoxP3+ cells is characteristic for the medullary subtype

Anz, David ; Eiber, Stephan ; Scholz, Christoph ; Endres, Stefan ; Kirchner, Thomas ; Bourquin, Carole ; Mayr, Doris

In: Histopathology, 2011, vol. 59, no. 5, p. 965–974

Aims: Medullary breast cancer (MBC) is a biologically distinct subtype of breast cancer characterized by prominent lymphocytic infiltrates and a favourable clinical outcome. Tumour-infiltrating CD8+ effector T cells may contribute to the good prognosis of this type of cancer; however, certain subtypes of lymphocyte, such as FoxP3+ regulatory T cells (Tregs), can also suppress antitumour...